03 September 2010
Keywords: PharmaMar, Centocor Ortho, Yondelis, Zeltia, Sarcoma, Ovarian cancer
Article | 17 March 2010
Centocor Ortho Biotech Products, a Johnson & Johnson subsidiary that has licensed rights in certain markets for Yondelis (trabectedin) from PharmaMar, part of Spain’s Grupo Zeltia, says that the regulatory authorities in Israel, Panama and Ukraine have approved the drug for advanced soft tissue sarcoma (STS) in adults. Furthermore, the authorities in Paraguay and Azerbaijan have cleared the drug for platinum-sensitive recurrent ovarian cancer (ROC). Yondelis is already approved for STS in Paraguay and Azerbaijan.
Zeltia recently reported 2009 sales of (123.4 million euros ($169.8 million) in 2009, up 17.2% on 2008, with Biopharmaceutical revenues expanded 53.3% due primarily to sales of Yondelis, which totaled 44.12 million euros last year. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscriptions are £60 per month, pay as you go.
Find out more details.